Acumen Pharma Files 8-K on Financials & Corporate Deck

Ticker: ABOS · Form: 8-K · Filed: Mar 26, 2026 · CIK: 0001576885

Acumen Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyAcumen Pharmaceuticals, INC. (ABOS)
Form Type8-K
Filed DateMar 26, 2026
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, corporate-presentation, regulation-fd, results-of-operations

TL;DR

**Acumen Pharma just dropped an 8-K with financial updates and a corporate presentation.**

AI Summary

Acumen Pharmaceuticals, Inc. filed an 8-K on March 26, 2026, disclosing its results of operations and financial condition, along with a corporate presentation. This filing includes an exhibit (EX-99.2) titled 'acumen_ncxcorporatexdeck.htm', which is likely a corporate deck providing updates on their business. This matters to investors because it provides current financial and operational insights, which can influence their decision to buy, hold, or sell the stock based on the company's performance and future outlook.

Why It Matters

This filing provides investors with the latest financial results and a corporate presentation, offering crucial insights into Acumen Pharmaceuticals' current performance and strategic direction.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the content of the financial results and corporate deck could contain information that impacts the company's risk profile, depending on the specifics of their operations and financial health.

Analyst Insight

A smart investor would review the attached EX-99.1 and EX-99.2 documents, especially the corporate deck, to understand the detailed financial results and strategic updates provided by Acumen Pharmaceuticals, Inc. before making any investment decisions.

Key Players & Entities

FAQ

What specific items were reported in Acumen Pharmaceuticals' 8-K filing on March 26, 2026?

The 8-K filing by Acumen Pharmaceuticals, Inc. on March 26, 2026, reported under Item 2.02: Results of Operations and Financial Condition, and Item 7.01: Regulation FD Disclosure.

What type of additional documents were included as exhibits in this 8-K filing?

The filing included EX-99.1 and EX-99.2. Specifically, EX-99.2 is described as 'acumen_ncxcorporatexdeck.htm', which appears to be a corporate presentation deck.

When was this 8-K filing accepted by the SEC?

The 8-K filing was accepted by the SEC on March 26, 2026, at 07:04:37.

What is the purpose of Item 2.02 in an 8-K filing?

Item 2.02 of an 8-K filing, 'Results of Operations and Financial Condition,' is used to disclose material information regarding a company's financial performance, often including earnings releases or other financial updates.

How many graphic files were included as part of the 'acumen_ncxcorporatexdeck.htm' exhibit?

The filing lists numerous graphic files (acumen_ncxcorporatexdeck001.jpg through acumen_ncxcorporatexdeck043.jpg), indicating at least 43 graphic files were part of or related to the corporate deck exhibit.

Filing Stats: 739 words · 3 min read · ~2 pages · Grade level 11 · Accepted 2026-03-26 07:04:37

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On March 26, 2026, Acumen Pharmaceuticals, Inc. (the " Company ") reported financial results and business highlights for the year ended December 31, 2025. A copy of this press release (the " Earnings Press Release ") is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this " Report ") and is incorporated by reference. The information in this Item 2.02 of this Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 26, 2026, the Company posted an updated corporate presentation to its website at https://investors.acumenpharm.com/news-events/presentations, which the Company may use from time to time in communications or conferences. The corporate presentation was updated to reflect the Company's cash, cash equivalents and marketable securities balance as of December 31, 2025 and to include the private placement completed by the Company on March 16, 2026. A copy of the corporate presentation is attached as Exhibit 99.2 to this Report. The information in this Item 7.01 of this Report (including Exhibit 99.2), is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company's submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d). Exhibits Exhibit No. Description 99.1 Earnings Press Release, dated March 26, 2026 99.2 Corporate Presentation, dated March 26, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acumen Pharmaceuticals, Inc. Dated: March 26, 2026 By: /s/ Matthew Zuga Matthew Zuga Chief Financial Officer and Chief Business Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing